WallStreetZenWallStreetZen

NASDAQ: VERA
Vera Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for VERA

Based on 4 analysts offering 12 month price targets for Vera Therapeutics Inc.
Min Forecast
$6.00-13.92%
Avg Forecast
$16.75+140.32%
Max Forecast
$38.00+445.19%

Should I buy or sell VERA stock?

Based on 4 analysts offering ratings for Vera Therapeutics Inc.
Buy
Strong Buy
1 analysts 25%
Buy
1 analysts 25%
Hold
2 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their VERA stock forecasts and price targets.

VERA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Jefferies
Bottom 10%
10
HoldDowngrades$6.00-13.92%2023-01-04
Wedbush
Bottom 4%
4
HoldDowngrades$8.00+14.78%2023-01-04
HC Wainwright & Co.
Top 11%
90
BuyMaintains$15.00+115.21%2023-01-04
JP Morgan
Bottom 1%
1
Strong BuyMaintains$38.00+445.19%2022-11-18

1 of 1

Forecast return on equity

Is VERA forecast to generate an efficient return?
Company
N/A
Industry
0.02%
Market
13.26%

Forecast return on assets

Is VERA forecast to generate an efficient return on assets?
Company
N/A
Industry
0.14%

VERA earnings per share forecast

What is VERA's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
-$3.52
Avg 2 year Forecast
-$3.52
Avg 3 year Forecast
-$2.97

VERA revenue forecast

What is VERA's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$19.7M
Avg 2 year Forecast
$101.2M
Avg 3 year Forecast
$297.1M

VERA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VERA$6.97$16.75+140.32%Buy
KMPH$5.56$16.67+199.77%Strong Buy
MLEC$5.17N/AN/A
CTXR$1.33$6.67+401.20%Strong Buy
AKBA$1.07$1.63+51.87%Hold

Vera Therapeutics Stock Forecast FAQ

Is Vera Therapeutics Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: VERA) stock is to Buy VERA stock.

Out of 4 analysts, 1 (25%) are recommending VERA as a Strong Buy, 1 (25%) are recommending VERA as a Buy, 2 (50%) are recommending VERA as a Hold, 0 (0%) are recommending VERA as a Sell, and 0 (0%) are recommending VERA as a Strong Sell.

If you're new to stock investing, here's how to buy Vera Therapeutics stock.

What is VERA's earnings growth forecast for 2023-2025?

(NASDAQ: VERA) Vera Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 21.89%.

Vera Therapeutics's earnings in 2023 is -$73,464,000.On average, 5 Wall Street analysts forecast VERA's earnings for 2023 to be -$97,354,893, with the lowest VERA earnings forecast at -$139,947,658, and the highest VERA earnings forecast at -$80,760,309. On average, 4 Wall Street analysts forecast VERA's earnings for 2024 to be -$97,354,893, with the lowest VERA earnings forecast at -$141,607,117, and the highest VERA earnings forecast at -$59,740,502.

In 2025, VERA is forecast to generate -$82,143,191 in earnings, with the lowest earnings forecast at -$116,438,664 and the highest earnings forecast at -$52,272,940.

What is VERA's revenue growth forecast for 2025-2027?

(NASDAQ: VERA) Vera Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.69%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.2%.

Vera Therapeutics's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast VERA's revenue for 2025 to be $545,132,084, with the lowest VERA revenue forecast at $545,132,084, and the highest VERA revenue forecast at $545,132,084. On average, 3 Wall Street analysts forecast VERA's revenue for 2026 to be $2,798,676,592, with the lowest VERA revenue forecast at $512,247,150, and the highest VERA revenue forecast at $6,733,805,611.

In 2027, VERA is forecast to generate $8,216,061,511 in revenue, with the lowest revenue forecast at $3,879,011,668 and the highest revenue forecast at $13,823,565,048.

What is VERA's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: VERA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.14%.

What is VERA's Price Target?

According to 4 Wall Street analysts that have issued a 1 year VERA price target, the average VERA price target is $16.75, with the highest VERA stock price forecast at $38.00 and the lowest VERA stock price forecast at $6.00.

On average, Wall Street analysts predict that Vera Therapeutics's share price could reach $16.75 by Jan 4, 2024. The average Vera Therapeutics stock price prediction forecasts a potential upside of 140.32% from the current VERA share price of $6.97.

What is VERA's Earnings Per Share (EPS) forecast for 2023-2025?

(NASDAQ: VERA) Vera Therapeutics's current Earnings Per Share (EPS) is -$3.14. On average, analysts forecast that VERA's EPS will be -$3.52 for 2023, with the lowest EPS forecast at -$5.06, and the highest EPS forecast at -$2.92. On average, analysts forecast that VERA's EPS will be -$3.52 for 2024, with the lowest EPS forecast at -$5.12, and the highest EPS forecast at -$2.16. In 2025, VERA's EPS is forecast to hit -$2.97 (min: -$4.21, max: -$1.89).

What is VERA's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: VERA) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.